Article
Anaheim, Calif. - Combination therapy with biological responsemodifiers and careful and regular reassessment of refractory patients areof paramount importance in the effective treatment of cutaneous T-cell lymphoma,according to Carmela C. Vittorio, M.D.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.